Cervical cancer (IMPT): Small IMPT series (n=11) showed improved DVH parameters versus VMAT and potentially comparable target coverage to MRI-guided brachytherapy for patients unable to undergo brachytherapy; findings are preliminary and require validation.
Small patient series; NCCN does not list PBT for uterine neoplasms.
Mesothelioma: Feasibility studies with small cohorts indicate IMPT deliverability with lower mean doses to several OARs and acceptable acute toxicity; evidence insufficient to demonstrate superiority over other modalities.
Limited sample sizes and adjunct therapies confound interpretation.
Pancreatic cancer (SBPT): Retrospective series (n=49) after induction chemotherapy reported 2-year OS 67.6%, LC 73.0% and grade ≥3 GI toxicity 6.1%; authors caution limitations due to retrospective design and limited follow-up.
NCCN pancreatic guideline does not mention PBT.
Rectal cancer: A systematic review/meta-analysis (8 articles; 127 patients) showed PBT reduced irradiated small bowel, bladder, and pelvic bone marrow versus photon RT; clinical outcome data remain limited.
NCCN rectal cancer guideline does not list PBT.
Retroperitoneal/pelvic sarcoma: Retrospective comparisons indicate peri-operative advanced-modality RT (including PBRT or IMRT) improved local recurrence-free survival versus surgery alone but did not significantly change disease-specific survival; peri-operative morbidity was higher in RT groups and randomized data are needed.
Small cohorts; further randomized investigation recommended.
Choroidal melanoma: Large retrospective series (n=351) reported many patients retain useful vision after PBRT even with foveal involvement; retrospective design limits causal inference.
Dose variations studied; further study needed.
Thymic tumors: Prospective cohort and small institutional series reported excellent local control and low early toxicity with proton therapy and dosimetric advantages versus IMRT; longer follow-up and prospective trials are needed.
NCCN states PBT may be considered in certain circumstances for thymic tumors.
Intracranial germ cell tumors: Dosimetric comparisons demonstrate superior target coverage and greater sparing of normal brain structures with proton techniques; clinical benefit requires validation.
Pediatric CNS dosimetric rationale cited.
Atypical meningioma: Small retrospective series report variable local control with particle RT; no definitive evidence of superiority to photon RT.
Additional prospective data required.
Sacral chordoma: Case reports and small series describe use of particle therapy (proton/carbon) often achieving favorable local control; trials and larger series with longer follow-up are needed.
Limited sample sizes and retrospective designs.